Why I feel buying the AstraZeneca share price could destroy your retirement riches

Roland Head explains why he’s avoiding AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Buying shares in bad businesses may be the most obvious way to lose money in the stock market.

But there’s another way of losing money that’s almost as dangerous and is often overlooked. I’m talking about valuation. Paying too much for a stock can leave you sitting on a loss for years, while the wider market steams ahead.

The two companies I’m looking at today are good businesses, but they look too expensive to me.

Pharma buzz

FTSE 100 pharmaceutical firm AstraZeneca (LSE: AZN) may seem an unlikely choice for this article. Surely this company is conservatively valued, produces reliable profits and pays a generous dividend?

Unfortunately, this isn’t the case. AZN shares have risen by 47% over the last five years to an all-time high of more than £63, despite falling profits and rising debt.

This has left the group trading on 22.2 times 2019 forecast adjusted earnings, with a dividend yield of 3.5% — well below the FTSE 100 average of 4.3%.

In my view, this valuation is pricing in a lot of future progress. I’m also concerned that the company’s preferred measure of adjusted earnings may be flattering its performance, something my colleague G A Chester covered recently in more detail.

Worse than it looks?

Over the last four years, AstraZeneca’s net debt has risen from $7.8bn to $16.3bn. I believe one reason for this is the maintenance of the group’s $2.80 per share dividend.

You see, the company has paid out about $14bn in cash distributions to shareholders since 2015, but has only reported shareholder profits of $11.5bn.

These numbers tell me that Astra is relying heavily on borrowed cash to fund investments in new medicines, while paying out all of its profits (and more) to shareholders.

The situation reached a new low in March, when Astra decided to raise $3.5bn from shareholders just days after paying a dividend of $2.4bn. This seems ludicrous to me — if cash really is that tight, the dividend should be cut.

My verdict: AstraZeneca has an exciting pipeline of new products, but I think the price is far too high, given the group’s weak cash generation and steep valuation. I’d wait for a better opportunity to buy.

Down 13% as spending climbs

My next stock also operates in the pharmaceutical sector, producing antibodies for research labs. Shares in Abcam (LSE: ABC) have risen from about 140p to 1,221p over the last 10 years, valuing this business at over £2.5bn.

However, the stock is down by more than 14% at the time of writing. Today’s fall came after the company announced plans to increase spending on expansion and said its chief financial officer had resigned.

Slowdown?

I should explain that Abcam has delivered high profit margins and strong growth for some years. Profits doubled between 2013 and 2018, for example.

However, earnings per share for the year that ended on 30 June are expected to be broadly unchanged from the previous year. Looking ahead, analysts expect modest earnings growth of 7% for the current year.

With spending rising, it’s not clear to me whether Abcam will be able to maintain its historic operating profit margin of nearly 30%. This risk — plus slower growth — suggests to me that the stock’s forecast price/earnings ratio of 35 is rather high.

As with AstraZeneca, I think this is a good business, but in my view it’s too expensive at the moment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Abcam and AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Retirement Articles

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

1 dividend-growth stock I’d tuck away in my SIPP without hesitation

This income growth stock increased its dividend by over 700% in the last decade! Is it worth adding more shares…

Read more »

Young female analyst working at her desk in the office
Investing Articles

Here’s how I’d target a £23k second income with £300 a month

If I was building a shares portfolio today, here's how I'd go about it. With these strategies I stand a…

Read more »

Investing Articles

How I’d invest my first £1,000 in a SIPP

Investing the first £1,000 in an SIPP can be a daunting process, especially for new investors. Zaven Boyrazian explains what…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

Worried about tax raids? Here’s how I’m targeting a £44,526 passive income with shares

Investing in a Self-Invested Personal Pension (SIPP) or Individual Savings Account (ISA) can supercharge one's passive income, says Royston Wild.

Read more »

Investing Articles

How I’d invest within a SIPP to target a 7% dividend yield

Zaven Boyrazian explains the steps he’d take to target a high-yield, income-generating SIPP for 2024 and beyond by investing in…

Read more »

Investing Articles

No pension at 50? Here’s my SIPP investment plan to target £16k a year in passive income!

With disciplined saving, a solid investment plan and the tax benefits of a SIPP, it’s possible to turbocharge pension growth…

Read more »

Young woman holding up three fingers
Investing Articles

These 3 investing steps could make me an £11,680 passive income!

If I was starting out on my investing journey, here's how I'd try to build a robust passive income with…

Read more »

The words "what's your plan for retirement" written on chalkboard on pavement somewhere in London
Investing Articles

Small SIPP at 55? I’d take these steps to boost my retirement savings

With a consistent savings plan, sound strategy, and some wonderful tax relief in a SIPP, it’s possible to massively grow…

Read more »